The psoriasis therapy market has become increasingly lucrative owing to the growing use of biologics. The dominance of the tumor necrosis factor (TNF)-alpha inhibitors and interleukin (IL)-12/23 inhibitor ustekinumab (Janssen’s Stelara) is being challenged by the introduction of the highly effective IL-17 and IL-23 inhibitors. In particular, uptake of secukinumab (Novartis’s Cosentyx) has been remarkable in its first few years postlaunch, but the agent faces competition from the newer, more-efficacious IL-17 inhibitors (ixekizumab [Eli Lilly’s Taltz] and brodalumab [Bausch Health / LEO Pharma / Kyowa Hakko Kirin’s Siliq / Kyntheum / Lumicef]) along with IL-23 inhibitors (Janssen’s guselkumab [Tremfya], Merck / Sun Pharma‌ / Almirall’s tildrakizumab [Ilumya‌ / Ilumetri] and AbbVie’s risankizumab [Skyrizi]). Additionally, the landscape for the established biologics will change with the increasing availability and use of biosimilars.

  • How do interviewed KOLs view the efficacy and safety of the IL-17 inhibitors (Cosentyx, Taltz, Siliq / Kyntheum / Lumicef, UCB’s bimekizumab), and where are/will these agents be positioned in the psoriasis treatment algorithm?
  • What will be the impact of the IL-23 inhibitors (guselkumab, tildrakizumab, risankizumab, Eli Lilly’s mirikizumab), and how will they fare in the competitive psoriasis market?
  • How is the oral agent apremilast (Celgene’s Otezla) used for psoriasis treatment, and what are the other promising emerging oral therapies?
  • How fast will the uptake of biosimilars occur in psoriasis, and which brands will experience the most erosion in patient share and sales?


Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.

Primary research: 28 country-specific interviews with thought leaders.

Epidemiology: Number of diagnosed and drug-treated prevalent cases of psoriasis; number of diagnosed prevalent cases of psoriasis by severity.

Emerging therapies: Phase II: 11 drugs; Phase III/preregistration: 5 drugs; coverage of select preclinical and Phase I products.

Table of contents

  • Disease Landscape & Forecast
    • COVID-19
    • Key Findings
      • Key Findings
    • Key Updates
      • April 2020
      • November 2019
      • August 2019
      • July 2019
      • October 2018
    • Market Outlook
      • Key Findings
        • Key Findings
      • COVID-19: Areas of Potential Forecast Impact
        • COVID-19: Areas of Potential Forecast Impact
      • Market Drivers and Constraints
        • What Factors Are Constraining the Market for Psoriasis?
      • Drug-Class-Specific Trends
        • Tumor Necrosis Factor-Alpha Inhibitors
        • IL-12/23 Inhibitors
        • IL-17 Inhibitors
        • IL-23 Inhibitors
        • PDE4 Inhibitors
        • A3AR Inhibitors
        • Select Topical Agents
        • TYK2 Inhibitors
    • Forecast
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Etiology and Pathophysiology
        • Disease Overview
      • Etiology
      • Pathophysiology
        • Clinical Features
      • Key Pathways and Drug Targets
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • Diagnosed Prevalent Cases
        • Severity of Psoriasis
        • Diagnosed and Drug-Treated Cases of Psoriasis by Severity
    • Current Treatment
      • Key Findings
      • Treatment Goals
        • Key Physician Insights on Clinical End Points
      • Key Current Therapies
        • Overview
        • TNF-Alpha Inhibitors
        • IL-12/23 Inhibitors
        • IL-17 Inhibitors
        • IL-23 Inhibitors
        • PDE4 Inhibitors
        • Conventional Systemic Therapies
        • Topical Therapies
      • Medical Practice
        • Overview
        • Treatment Guidelines
        • Drug Selection
        • Country-Specific Treatment
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Psoriasis
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • IL-23 Inhibitors
        • IL-17 Inhibitors
        • A3 Adenosine Receptor Agonists
        • TYK2 Inhibitors
        • Emerging Topical Agents
      • Early-Phase Pipeline Analysis
    • Access & Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • Looking for More?
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • Agents Included in Our Market Analysis
        • General Statements About Pricing
        • Dosing, Days of Therapy, and Compliance
        • Generic Erosion
        • Biosimilar Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Psoriasis Bibliography

Author(s): Yingdee Unhavaithaya; T.J. Arndt, MPH, CPH

Yingdee Unhavaithaya is a Business Insights Analyst on the Immune and Inflammatory Disorders team at Decision Resources Group, primarily focusing on psoriasis. Prior to joining DRG, Yingdee was an analyst at Citeline, where he analyzed data on oncology clinical trials ; He was also a business development intern at the Massachusetts General Hospital Research Ventures and Licensing office, where he performed market research to look for invention licensing ; Yingdee received his in cell biology from the University of Massachusetts Medical School, and a in biology from the University of Pittsburgh at Greensburg.

joined Decision Resources Group in 2018 as an entry-level epidemiologist and previously worked in basic sciences research academia. earned his Masters in Public Health from the University of Florida, where he conducted an internship focused on developing a clinical model to non-invasively screen for Non-Alcoholic Steatohepatitis (NASH). He also holds a in Microbiology & Cell Science and a in Spanish, both from the University of Florida. During his undergraduate and graduate career, he worked in two physiology-based research labs at the University of Florida, focusing on maternal and fetal stresses during pregnancy and parturition.

Related Reports

Psoriasis | Disease Landscape and Forecast | G7 | 2019

The psoriasis therapy market has become increasingly lucrative owing to the growing use of biologics. The dominance of the tumor necrosis factor (TNF)-alp...

View Details

Psoriasis | Geographic Focus: China | Psoriasis|China In-Depth|China

Psoriasis is an incurable chronic skin condition known to affect more than 8 million people in China. China’s psoriasis market has grown significantly over the last few years owing to the g...

View Details

Psoriasis | Current Treatment | Detailed, Expanded Analysis Pediatric Psoriasis - Treatment Algorithms - Claims Data Analysis (US)

Psoriasis is a chronic, inflammatory autoimmune skin disease that can affect children, adolescents, and adults. Given the limited number of therapies approved for pediatric psoriasis, treatment o...

View Details

Psoriasis | Current Treatment | Detailed, Expanded Analysis Adult Psoriasis - Treatment Algorithms - Claims Data Analysis (US)

The adult psoriasis market has become increasingly lucrative owing to the growing use of biologics in the moderate to severe population, which cannot be adequately controlled with conventional sy...

View Details